abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] avermectin B1a (purity ≥80 %) [2]

abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] avermectin B1a (purity ≥80 %) [2] has acute toxicity (oral, dermal, or inhalation) classified as Category 1–3. Access to this substance must be restricted to trained personnel. Store in a locked, well-ventilated area. Exposure monitoring and medical surveillance may be required under OSHA 29 CFR 1910.1000 or equivalent regulations.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] avermectin B1a (purity ≥80 %) [2] is classified as a specific target organ toxicant (STOT). Exposure must be minimised using engineering controls (local exhaust ventilation, closed systems). Biological and medical monitoring may be required. Refer to the full Safety Data Sheet (SDS) Section 8 for occupational exposure limits.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] avermectin B1a (purity ≥80 %) [2] is hazardous to the aquatic environment. Do not allow this substance to enter drains, waterways, or soil. Spills must be contained immediately using appropriate absorbent material. Disposal must comply with local environmental regulations — consult the SDS Section 13 for guidance on waste treatment.

This substance carries the signal word DANGER, indicating the more severe hazard categories under GHS/CLP. Facilities handling abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] avermectin B1a (purity ≥80 %) [2] should ensure a written hazard communication programme, including current SDS, employee training records, and GHS-compliant labelling on all containers.